Multicentre, Non-randomised, Open-label Phase II Study to Evaluate the Efficacy and Safety of Induction Treatment With Rituximab, Fludarabine, Cyclophosphamide, Followed by Rituximab Maintenance Therapy (R-Fc-Rm) in the First Line Treatment of Chronic Lymphocytic Leukaemia
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2016
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 17 Jun 2016 Status changed from active, no longer recruiting to completed.
- 04 May 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.